Pancreatic cancer shows extremely low
responses to chemo- and radiation therapies due to its inherent genetic
instability, immunosuppressive microenvironment, and the complex peritumoral
stroma.
They make the pancreatic cancer most lethal
malignancy with 5 year survival of less than 6%, so the need of new therapeutic
approaches is urgently demanded. Immunotherapies have shown promises in other multiple cancers by
augmenting anti-tumor immunity, so it stood out for the alternative care of
pancreatic cancer.
However, up to now, immunotherapeutic agents
lack efficacy in pancreatic cancer. In this review, we give an overview of
immune-related therapeutic strategies, clinical trials in pancreatic cancer and
current obstacles that we face. We discuss the ways to overcome those current
obstacles here, and by getting over them, we hope to get over the poor
prognosis of pancreatic cancer.
No comments:
Post a Comment